{"id":"https://openalex.org/W4362526041","doi":"https://doi.org/10.1158/1535-7163.22499862","title":"Supplementary Materials and Methods and Supplementary Figure Legends from Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody\u2013Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect","display_name":"Supplementary Materials and Methods and Supplementary Figure Legends from Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody\u2013Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect","alternate_titles":[],"publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362526041","doi":"https://doi.org/10.1158/1535-7163.22499862"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22499862","doi":"https://doi.org/10.1158/1535-7163.22499862","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22499862","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"parent_works":[],"lineage":["https://openalex.org/W4362526041"],"child_works_count":0,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1535-7163.22499862","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005024069","display_name":"Sven Golfier","orcid":"https://orcid.org/0009-0005-6506-8182","observed_orcids":["https://orcid.org/0009-0005-6506-8182"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sven Golfier","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065895440","display_name":"Charlotte Kopitz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Charlotte Kopitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011022911","display_name":"Antje Kahnert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antje Kahnert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003818185","display_name":"Iring Heisler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Iring Heisler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017327688","display_name":"Christoph A. Schatz","orcid":"https://orcid.org/0000-0001-8028-2631","observed_orcids":["https://orcid.org/0000-0001-8028-2631"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christoph A. Schatz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040976235","display_name":"Beatrix Stelte\u2010Ludwig","orcid":"https://orcid.org/0000-0002-1045-1134","observed_orcids":["https://orcid.org/0000-0002-1045-1134"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Beatrix Stelte-Ludwig","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076775447","display_name":"Anke Mayer\u2010Bartschmid","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anke Mayer-Bartschmid","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023005940","display_name":"Kerstin Unterschemmann","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kerstin Unterschemmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048811845","display_name":"Sandra Bruder","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sandra Bruder","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105990213","display_name":"Lars Lind\u00e9n","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lars Linden","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014719891","display_name":"Axel Harrenga","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Axel Harrenga","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005601638","display_name":"Peter Hauff","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Hauff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019923187","display_name":"Frank-Detlef Scholle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Frank-Detlef Scholle","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034517379","display_name":"Beate M\u00fcller\u2010Tiemann","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Beate M\u00fcller-Tiemann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048269157","display_name":"Bertolt Kreft","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bertolt Kreft","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5051451842","display_name":"Karl B. Ziegelbauer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karl Ziegelbauer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6015999913215637,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6015999913215637,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.17579999566078186,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.03290000185370445,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mesothelin","display_name":"mesothelin","score":0.925000011920929},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9800000190734863},{"id":"https://openalex.org/keywords/bystander-effect","display_name":"bystander effect","score":0.9819999933242798},{"id":"https://openalex.org/keywords/tumor-targeting","display_name":"tumor targeting","score":0.47600001096725464},{"id":"https://openalex.org/keywords/cancer-therapy","display_name":"cancer therapy","score":0.5559999942779541}],"concepts":[{"id":"https://openalex.org/C2777045440","wikidata":"https://www.wikidata.org/wiki/Q14914057","display_name":"Mesothelin","level":3,"score":0.9670885801315308},{"id":"https://openalex.org/C19106626","wikidata":"https://www.wikidata.org/wiki/Q230749","display_name":"Bystander effect","level":2,"score":0.8226853609085083},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.6879326701164246},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.5640569925308228},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5318533778190613},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.468117892742157},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3786773979663849},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3398408889770508},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.24542412161827087},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.17533719539642334},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.17467135190963745},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.22499862","doi":"https://doi.org/10.1158/1535-7163.22499862","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22499862","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1535-7163.22499862.v1","doi":"https://doi.org/10.1158/1535-7163.22499862.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22499862.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Materials_and_Methods_and_Supplementary_Figure_Legends_from_Anetumab_Ravtansine_A_Novel_Mesothelin-Targeting_Antibody_Drug_Conjugate_Cures_Tumors_with_Heterogeneous_Target_Expression_Favored_by_Bystander_Effect/22499862/1/files/39959133.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22499862","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Materials_and_Methods_and_Supplementary_Figure_Legends_from_Anetumab_Ravtansine_A_Novel_Mesothelin-Targeting_Antibody_Drug_Conjugate_Cures_Tumors_with_Heterogeneous_Target_Expression_Favored_by_Bystander_Effect/22499862","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22499862","doi":"https://doi.org/10.1158/1535-7163.22499862","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22499862","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.6240000128746033}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362526041.pdf","grobid_xml":"https://content.openalex.org/works/W4362526041.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4392687903","https://openalex.org/W2138654358","https://openalex.org/W2768037094","https://openalex.org/W4251910366","https://openalex.org/W2889648227","https://openalex.org/W3013332534","https://openalex.org/W3050359840","https://openalex.org/W2642476213","https://openalex.org/W4245258717","https://openalex.org/W4200092748"],"abstract_inverted_index":{"PDF":[0],"-":[1],"117K,":[2],"Supplementary":[3],"materials":[4],"and":[5,12],"methods,":[6],"figure":[7],"legends":[8],"for":[9],"supplementary":[10],"figures":[11],"table.":[13]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4362526041","counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2023-04-06T00:00:00"}
